Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age

Table 3 Incidence of drug-related adverse events of sorafenib treatment

Adverse event, %	SHARP[5]	AP[6]	GIDEON (second interim analysis)[89]
	(n = 297)	(n = 149)	(n = 1571)
Any adverse event	80	82	64
Diarrhea	39	26	25
Hand-foot skin reaction	21	45	24
Fatigue	22	20	14
Rash⁄desquamation	16	20	12
Anorexia	14	13	9
Hypertension	5	19	7
Alopecia	14	25	7
Nausea	11	11	6
Weight loss	9	NA1	5

¹NA: Not available; this adverse event was observed in < 10% of patients in AP trial. Incidence of all grades of adverse events was shown. Adverse events in ≥ 5% of the total population in GIDEON study were listed.